Fundraising FoxKailos Genetics
Huntsville, US · Founded 2010 · Delaware corporation · 2 known investors
Find your way into Kailos Genetics
355 people in our graph can introduce you to the Kailos Genetics team.
Sign up to see every warm intro you have to Kailos Genetics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Kailos Genetics team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Kailos Genetics is a biotechnology company with expertise in medical and biotechnology industries.
Founders & leadership
RC
Randall C. BachmeyerExecutive
BK
Brian K. PollockCo-founder and CEO2010–2025Brian Pollock co-founded Kailos Genetics, a molecular diagnostic company, which he led as CEO for 15 years; previously he co-founded and served as CEO of Open Biosystems through its acquisition by Thermo Fisher Scientific, and held senior roles at Invitrogen and Research Genetics in genomics.
OA
Ogan AbaanVice President of Lab OperationsHe brings 15+ years of experience in precision medicine and genomics, including work on large-scale sequencing initiatives, government contracting programs, and next-generation sequencing applications.
DT
David Troy MooreNamed on SEC filing
RM
Ron McGlennenMedical Director
DK
David KloskeDirector of Bioinformatics
Board
JR
James R. Hudson, Jr.Board director
KT
Katherine T. VarleyBoard director
DW
Danny WindhamBoard director
MJ
Michael J. WaltersBoard director
Investors · 2
New Capital Partnerslisted by New Capital PartnersBirmingham · $5M – $100M
How we know: New Capital Partners's portfolio page · Not right? Tell us
In-Q-TelreportedTysons · $100K – $2.5M
How we know: funding news · press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$2M disclosed across 1 of 4 rounds · 2014–2018
▶$2MraisedApr 2018 · 8 investors · BiotechnologyRule 506(b)
▶$2MraisedApr 2018 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael J. WaltersDirector
- Danny WindhamDirector
- David Troy MooreExecutive Officer, Director
- Brian K. PollockExecutive Officer, Director
- Randall C. BachmeyerExecutive Officer
- Cheri WalkerExecutive Officer
- James R. Hudson, Jr.Director
- Katherine T. VarleyDirector
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MofferedNov 2016 · BiotechnologyRule 506(b)
▶$2MofferedNov 2016 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael J. WaltersDirector
- Katherine T. VarleyDirector
- Randall C. BachmeyerExecutive Officer
- David Troy MooreExecutive Officer, Director
- Brian K. PollockExecutive Officer, Director
- Offering amount
- $2M
- Minimum investment
- $25K
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MofferedAug 2015 · BiotechnologyRule 506(b)
▶$4MofferedAug 2015 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Katherine T. VarleyDirector
- Randall C. BachmeyerExecutive Officer
- Brian K. PollockExecutive Officer, Director
- James R. Hudson, Jr.Director
- Danny WindhamDirector
- David Troy MooreExecutive Officer, Director
- Michael J. WaltersDirector
- Cheri L. WalkerExecutive Officer
- Offering amount
- $4M
- Minimum investment
- $100K
- Proceeds to insiders
- $180K
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MofferedJul 2014 · BiotechnologyRule 506(b)
▶$2.5MofferedJul 2014 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David Troy MooreExecutive Officer, Director
- Michael J WaltersExecutive Officer, Director
- Randall C BachmeyerExecutive Officer
- James R. Hudson, Jr.Director
- Danny WindhamDirector
- Katherine T VarleyDirector
- Brian PollockExecutive Officer, Director
- Offering amount
- $2.5M
- Minimum investment
- $100K
- Incorporated
- Corporation, Delaware, 2010
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
American Cancer Society (ACS)The American Cancer Society is a nonprofit organization that provides cancer research updates, screening and prevention guidance, and community engagement opportunities. It serves individuals seeking cancer information and those who want to support cancer research and patient advocacy efforts.
MD Anderson Cancer CenterUT MD Anderson is a cancer research and treatment center that provides patient care, conducts research, and offers education in cancer prevention and treatment. It is part of the University of Texas System and operates as a nonprofit medical institution.
CancerresearchukCancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.
Companies working in the same space as Kailos Genetics.
In the news
Frequently asked questions
- What does Kailos Genetics do?
- Kailos Genetics is a biotechnology company with expertise in medical and biotechnology industries.
- Who are Kailos Genetics's investors?
- Kailos Genetics's investors include New Capital Partners, In-Q-Tel.
- How much funding has Kailos Genetics raised?
- Kailos Genetics has disclosed $2M raised across 1 of its 4 known rounds.
- Where is Kailos Genetics headquartered?
- Kailos Genetics is headquartered in Huntsville, US.